Stock Market Reviews

RXRX (Recursion Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on RXRX (Recursion Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Cathie Wood Keeps Dumping Tesla Stock -- Here is Why
  Cathie Wood Sells Tesla, Boosts Crypto Bets in ARK Portfolio
  Dec 19, 2025 - $RXRX
• Why Recursion Pharmaceuticals, Inc. (RXRX)’s Upside Case Hasn’t Fully Convinced Yet
  Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from 71% of the analysts covering the stock. With a median price target of $6, the stock has an upside potential of 42.86%. On December 9, Alec […]
  Dec 18, 2025 - $RXRX
• Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday
  Sentiment on the company has improved following solid clinical trial results from one of its pipeline drugs earlier this month.
  Dec 17, 2025 - $RXRX
• Is There an Opportunity in Recursion Pharmaceuticals After Recent AI Drug Discovery Rally?
  Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced about 10.8% over the last week and 4.5% over the past month, but it is still down roughly 33% year to date and 41.6% over the last year, which indicates that sentiment has gone through a rough reset. That rebound has come as investors refocus on Recursion's ambitious push to apply AI and...
  Dec 9, 2025 - $RXRX
• Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
  REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baselineNatural history analysis showed that 87% of untreated FAP patients - who resembled the inclusion criteria of TUPELO - had a
  Dec 8, 2025 - $RXRX
• Jim Cramer on Recursion: “It Is so Low That It Comes in Under the Category of Speculative”
  Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer said: “I’m telling you, I am myself confounded by it. The stock has been horrendous. We gotta put that right on the table. I’m talking about […]
  Dec 8, 2025 - $RXRX
• Recursion Pharmaceuticals (RXRX) Is Up 8.0% After TUPELO REC-4881 Trial Data Release - What's Changed
  In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This trial update matters because clinical readouts can materially influence how investors view Recursion’s ability to turn its AI-driven discovery platform into viable therapies. Next, we’ll examine how the TUPELO REC-4881 data readout may reshape Recursion’s AI-focused investment narrative and...
  Dec 8, 2025 - $RXRX
• Why Recursion Pharamaceuticals Topped the Market Today
  The company appears to be on track to develop a commercialized product through its drug discovery system.
  Dec 8, 2025 - $RXRX
• 1 Nvidia-Backed Artificial Intelligence Stock to Buy Hand Over Fist in 2026
  Nvidia holds equity stakes in a number of public companies.
  Dec 7, 2025 - $RXRX
• Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue?
  Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 5, 2025 - $RXRX